{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://www.immunitastx.com/#organization",
      "name": "Immunitas",
      "url": "https://www.immunitastx.com/",
      "description": "Immunitas 0 Skip to Content Our Biology News Contact Open Menu Close Menu Our Biology News Contact Open Menu Close Menu Our Biology News Contact NOVEL BIOLOGY PATIENT IMPACT Immunitas was founded to discover and develop novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 for treatment of solid tumors and hematological malignancies. Our second program, recently licensed to Boehringer Ingelheim, is a novel therapeutic for the treatment of autoimmune disease."
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/immunitas#asg",
      "name": "Immunitas ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/immunitas",
      "isPartOf": {
        "@id": "https://www.immunitastx.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}